Aptafin S P A - Net Worth and Insider Trading

Aptafin S P A Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Aptafin S P A owns 1 companies in total, including Regenerx Biopharmaceuticals Inc (RGRX) .

Click here to see the complete history of Aptafin S P A’s form 4 insider trades.

Insider Ownership Summary of Aptafin S P A

Ticker Comapny Transaction Date Type of Owner
RGRX Regenerx Biopharmaceuticals Inc 2021-06-30 other: Member of 10% owner group

Aptafin S P A Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Aptafin S P A Ownership Network

Ownership Network List of Aptafin S P A

No Data

Ownership Network Relation of Aptafin S P A

Insider Network Chart

Aptafin S P A Owned Company Details

What does Regenerx Biopharmaceuticals Inc do?

Who are the key executives at Regenerx Biopharmaceuticals Inc?

Aptafin S P A is the other: Member of 10% owner group of Regenerx Biopharmaceuticals Inc. Other key executives at Regenerx Biopharmaceuticals Inc include 10 percent owner Spa Essetifin , 10 percent owner Francesca Cavazza , and 10 percent owner Silvia Cavazza .

Regenerx Biopharmaceuticals Inc (RGRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regenerx Biopharmaceuticals Inc (RGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regenerx Biopharmaceuticals Inc (RGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regenerx Biopharmaceuticals Inc (RGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regenerx Biopharmaceuticals Inc Insider Transactions

No Available Data

Aptafin S P A Mailing Address

Above is the net worth, insider trading, and ownership report for Aptafin S P A. You might contact Aptafin S P A via mailing address: Viale Shakespeare 47, Rome L6 00144.

Discussions on Aptafin S P A

No discussions yet.